VERASTEM, INC.
NEEDHAM, MA

Verastem, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies aimed at significantly improving patient outcomes in cancer treatment. The company leverages deep expertise and strategic agility to identify and advance late-stage, first-in-class clinical assets towards the market. Its focus is on creating small molecule drugs that inhibit critical signaling pathways implicated in cancer, such as phosphoinositide 3-kinase (PI3K) and focal adhesion kinase (FAK), which are known to contribute to tumor survival and resistance to existing treatments. Verastem's lead clinical product candidate, defactinib, targets the FAK pathway and is under evaluation in clinical collaborations using combination therapies with immunotherapeutic agents. These collaborative studies focus on treating several cancer types including pancreatic, ovarian, non-small cell lung cancer (NSCLC), and mesothelioma. The company's management team includes Mr. Paterson, who brings over 25 years of experience in healthcare and biotechnology management, particularly in oncology product development and corporate strategy. Additionally, Mr. Bloom serves as the Chief Strategy Officer overseeing key areas such as Corporate Development, Medical Affairs, and Communications. Verastem is incorporated in Florida under status code F18000001055 with its registered office located at 117 Kendrick Street, Suite 500, Needham, MA. The company's last annual report was filed on April 12, 2024. For more information, visit the Verastem website or contact them via their provided phone numbers.